Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ASP3026 是一种选择性的,具有口服活性的间变性淋巴瘤激酶抑制剂,可诱导肿瘤细胞凋亡,可研究非小细胞肺癌。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 169 | 现货 | ||
5 mg | ¥ 378 | 现货 | ||
10 mg | ¥ 547 | 现货 | ||
25 mg | ¥ 890 | 现货 | ||
50 mg | ¥ 1,330 | 现货 | ||
100 mg | ¥ 2,150 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 779 | 现货 |
产品描述 | ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS. |
靶点活性 | ALK:3.5 nM |
体外活性 | 以每天两次口服给药ASP3026的方式处理荷有皮下NCI-H2228肿瘤异种移植物的小鼠14天,诱导剂量依赖性的抗肿瘤作用,从1 mg/kg开始,在10,30和100 mg/kg强烈消退. |
体内活性 | ASP3026抑制内源性表达EML4-ALK变体3的人NSCLC肿瘤细胞系NCI-H2228的生长,IC50值为64.8 nM。ASP3026在酪氨酸激酶中比PF02341066显示更强的选择性抑制ALK活性。 |
激酶实验 | Recombinant truncated FLAG-tagged mTOR expressed in HEK 293 cells is used in biochemical assays, together with a biotinylated p70S6K peptide substrate. Streptavidin donor and protein A acceptor beads are used to assemble the capture complex for generation of the assay signal. The activity of the lipid kinases, PI3K alpha, beta, delta, and gamma are measured using recombinant proteins and the lipid PIP2 as substrate. Assays for ATM and DNA-PK activity are performed. The mTOR cellular activity is measured in MDAMB468 cells, using an Acumen laser scanning cytometer to analyze the levels of phosphorylation of S6 (Ser235/236) and AKT (Ser473)[1]. |
别名 | ASP 3026 |
分子量 | 580.74 |
分子式 | C29H40N8O3S |
CAS No. | 1097917-15-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11.6 mg/mL (20 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7219 mL | 8.6097 mL | 17.2194 mL | 43.0485 mL |
5 mM | 0.3444 mL | 1.7219 mL | 3.4439 mL | 8.6097 mL | |
10 mM | 0.1722 mL | 0.861 mL | 1.7219 mL | 4.3049 mL | |
20 mM | 0.0861 mL | 0.4305 mL | 0.861 mL | 2.1524 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ASP3026 1097917-15-1 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors ALK inhibit ALK tyrosine kinase receptor Anaplastic lymphoma kinase (ALK) Inhibitor ASP-3026 Cluster of differentiation 246 ASP 3026 Anaplastic lymphoma kinase CD246 inhibitor